Sequential Low-dose Decitabine With PD-1/CD28 CD19 CAR-T in Relapsed or Refractory B-cell Lymphoma

NCT04850560 · clinicaltrials.gov ↗

PHASE1

Phase

UNKNOWN

Status

30

Enrollment

OTHER

Sponsor class

Conditions

Objective Response Rate

Interventions

BIOLOGICAL: CD19 PD-1/CD28 CAR-T Plus Low Dose Decitabine

Sponsor

Second Affiliated Hospital, School of Medicine, Zhejiang University